Submissions

Request for extension of comment period regarding Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Including Drugs that are Regulated Under a Biologics License Application, and Animal Drugs.

Letter to the FDA's LT Darrell Lyons requesting additional time to address the Nonprescription Drugs Advisory Committee.

The Consumer Healthcare Products Association welcomes the opportunity to present its recommendations for CFSAN’s top priorities for the upcoming fiscal year and congratulates FDA on its achievements of the previous year.

While DXM is used safely by millions of Americans, some teenagers and young adults are intentionally abusing large quantities of medicines containing DXM in an effort to get high.

CHPA appreciates the opportunity to provide comments to the Food and Drug Administration on the proposed experimental study of qualified health claims about omega-3 fatty acids.

CHPA appreciates the comments of FDA in the February 2006, feedback letter and understands that these comments are FDA’s best advice on designing a protocol to address the safety and efficacy of benzocaine. We have included a revised final protocol for your final review.

Letter from the Consumer Healthcare Products Association, the Food Marketing Institute, the Healthcare Distribution Management Association, and the National Association of Chain Drugstores regarding controlled substances and Lis I chemical registration application fees.

With this letter, the Consumer Healthcare Products Association expresses its great interest in the selection of the industry representative to serve on the Nonprescription Drugs Advisory Committee.